The estimated Net Worth of David N Gill is at least $963 millier dollars as of 13 May 2024. Mr. Gill owns over 10,361 units of Y-Mabs Therapeutics Inc stock worth over $450,702 and over the last 18 years he sold YMAB stock worth over $268,642. In addition, he makes $243,622 as Independent Director at Y-Mabs Therapeutics Inc.
Sign up
Mr. Gill YMAB stock SEC Form 4 insiders trading
David has made over 14 trades of the Y-Mabs Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 10,361 units of YMAB stock worth $130,963 on 13 May 2024.
The largest trade he's ever made was selling 10,361 units of Y-Mabs Therapeutics Inc stock on 13 May 2024 worth over $130,963. On average, David trades about 1,340 units every 62 days since 2006. As of 13 May 2024 he still owns at least 33,964 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mr. Gill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Gill biography
David N. Gill CPA serves as Independent Director of the Company. Mr. Gill served as the President and Chief Financial Officer of EndoChoice, Inc., a medical device company focused on gastrointestinal disease, from April 2016 through the sale of the company in November 2016 and as Chief Financial Officer from August 2014 to November 2016. Previously, he served as the Chief Financial Officer of INC Research (now known as Syneos Health), a clinical research organization, from February 2011 to August 2013 after having served as a board member and its audit committee chairman from 2007 to 2010. Mr. Gill also currently serves on the boards of Evolus, Inc. (Nasdaq: EOLS), Strata Skin Sciences, Inc. (Nasdaq: SSKN) and Strongbridge Biopharma plc. (Nasdaq: SBBP). He previously served on the board of Histogenics, Inc. (now Ocugen, Inc.) and Melinta Therapeutics, Inc. Earlier in his career, Mr. Gill served in a variety of senior executive leadership roles for several publicly-traded companies, including NxStage Medical, CTI Molecular Imaging, Inc., Interland Inc. and Novoste Corporation. Mr. Gill holds a B.S. degree, cum laude, in accounting from Wake Forest University and an M.B.A. degree, with honors, from Emory University, and was formerly a certified public accountant. Mr. Gill currently serves as Chair of our Audit Committee, as a member of our Compensation Committee and our Nominating and Corporate Governance Committee.
What is the salary of David Gill?
As the Independent Director of Y-Mabs Therapeutics Inc, the total compensation of David Gill at Y-Mabs Therapeutics Inc is $243,622. There are 6 executives at Y-Mabs Therapeutics Inc getting paid more, with Claus Moller-San Pedro having the highest compensation of $967,497.
How old is David Gill?
David Gill is 65, he's been the Independent Director of Y-Mabs Therapeutics Inc since 2017. There are 2 older and 17 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
What's David Gill's mailing address?
David's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Insiders trading at Y-Mabs Therapeutics Inc
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad et Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
What does Y-Mabs Therapeutics Inc do?
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
What does Y-Mabs Therapeutics Inc's logo look like?
Complete history of Mr. Gill stock trades at Lemaitre Vascular Inc, STRATA Skin Sciences Inc, Strongbridge Biopharma plc, Evolus Inc et Y-Mabs Therapeutics Inc
Y-Mabs Therapeutics Inc executives and stock owners
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
CEO & Director -
Claus Moller-San Pedro,
Chief Executive Officer, Director -
Thomas Gad,
Chairman of the Board, President, Founder, Head of Business Development and Strategy -
Thomas Gad,
Founder, Chairman, Pres and Head of Bus. Devel. & Strategy -
Bo Kruse,
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director -
Bo Kruse,
Exec. VP, Sec., Treasurer & CFO -
David Gill,
Independent Director -
James Healy,
Independent Director -
Ashutosh Tyagi,
Independent Director -
Gerard Ber,
Independent Director -
Johan Wedell-Wedellsborg,
Independent Director -
Torben Lund-Hansen,
Senior Vice President, Chief Technical Officer -
Steen Lisby,
Senior Vice President, Chief Medical Officer -
Philip Herman,
Senior Vice President and Chief Commercial Officer -
Mahiuddin Ahmed,
Senior Vice President, Chief Scientific Officer -
Joris Wilms,
Chief Operating Officer, Senior Vice President -
Sue Smith,
Sr. VP & Chief Commercial Officer -
Dr. Torben Lund-Hansen,
Sr. VP & Chief Technical Officer -
Joris Wiel Jan Wilms,
Sr. VP & COO -
Dr. Vignesh Rajah,
Sr. VP & Chief Medical Officer -
Dr. Steen Lisby M.D., M.Sc.,
Sr. VP & Chief Scientific Officer -
Peter P. Pfreundschuh,
CFO and Treasurer -
Gregory S Raskin,
Director -
Ashu Tyagi,
Director -
Mary Tagliaferri,
Director -
Laura Hamill,
Director -
Vignesh Rajah,
SVP & CHIEF MEDICAL OFFICER -
Biotech Ap S Wg,
Director -
Susan Laura Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Michael J Rossi,
PRESIDENT & CEO